PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277787
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through
      XIAP Down-regulation and Autophagy Inhibition.
PG  - 301-306
AB  - BACKGROUND/AIM: To investigate whether XIAP down-regulation and autophagy
      inhibition sensitize ovarian clear cell cancer cells to cisplatin. MATERIALS AND 
      METHODS: The ovarian clear cancer cell line KK was used for in vitro analysis.
      Hydroxychloroquine (HCQ) and phenoxodiol (PXD) or embelin were used as autophagy 
      and XIAP inhibitors, respectively. Non-specific and XIAP-specific siRNAs were
      transfected using Lipofectamine. Cytotoxicity was assessed by MTT assays. Protein
      expression was confirmed by western blotting. RESULTS: In KK, down-regulation of 
      XIAP using specific siRNAs together with HCQ treatment enhanced the anti-tumor
      effect of cisplatin. Although embelin sensitized KK to cisplatin through XIAP
      down-regulation, it induced autophagy. However, PXD increased cisplatin
      sensitivity through XIAP down-regulation and autophagy inhibition. Expression of 
      Atg7, Atg12, and Beclin 1 was decreased after PXD treatment. CONCLUSION: PXD
      increased cisplatin sensitivity through XIAP down-regulation and autophagy
      inhibition and could be a new candidate for ovarian clear cell carcinoma
      treatment.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Miyamoto, Morikazu
AU  - Miyamoto M
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan [email protected]
FAU - Takano, Masashi
AU  - Takano M
AD  - Department of Clinical Oncology, National Defense Medical College Hospital,
      Tokorozawa, Japan.
FAU - Aoyama, Tadashi
AU  - Aoyama T
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Soyama, Hiroaki
AU  - Soyama H
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Ishibashi, Hiroki
AU  - Ishibashi H
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Kato, Kento
AU  - Kato K
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Iwahashi, Hideki
AU  - Iwahashi H
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Takasaki, Kazuki
AU  - Takasaki K
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Kuwahara, Mika
AU  - Kuwahara M
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Matuura, Hiroko
AU  - Matuura H
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Sakamoto, Takahiro
AU  - Sakamoto T
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
FAU - Yoshikawa, Tomoyuki
AU  - Yoshikawa T
AD  - Department of Clinical Oncology, National Defense Medical College Hospital,
      Tokorozawa, Japan.
FAU - Furuya, Kenichi
AU  - Furuya K
AD  - Department of Obstetrics and Gynecology, National Defense Medical College
      Hospital, Tokorozawa, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzoquinones)
RN  - 0 (Isoflavones)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (X-Linked Inhibitor of Apoptosis Protein)
RN  - 0 (XIAP protein, human)
RN  - 995FT1W541 (phenoxodiol)
RN  - Q20Q21Q62J (Cisplatin)
RN  - SHC6U8F5ER (embelin)
SB  - IM
MH  - Adenocarcinoma, Clear Cell/genetics/*metabolism
MH  - Antineoplastic Agents/*pharmacology
MH  - Autophagy/drug effects
MH  - Benzoquinones/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Cisplatin/*pharmacology
MH  - Down-Regulation
MH  - Female
MH  - Humans
MH  - Isoflavones/*pharmacology
MH  - Ovarian Neoplasms/genetics/*metabolism
MH  - RNA, Small Interfering/genetics
MH  - X-Linked Inhibitor of Apoptosis Protein/genetics/*metabolism
OTO - NOTNLM
OT  - *Ovarian clear cell carcinoma
OT  - *X-chromosome-linked inhibitor of apoptosis (XIAP)
OT  - *autophagy
OT  - *phenoxodiol
OT  - *platinum resistance
EDAT- 2017/12/27 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/11/13 00:00 [received]
PHST- 2017/11/24 00:00 [revised]
PHST- 2017/11/27 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 38/1/301 [pii]
AID - 10.21873/anticanres.12222 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):301-306. doi: 10.21873/anticanres.12222.